Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in children and adolescents ages 6 17 years with type 1 diabetes mellitus: A 12 month, outpatient, randomized, open label, parallel group comparative trial

Trial Profile

Safety and efficacy of Exubera (inhaled insulin) compared with subcutaneous human insulin therapy in children and adolescents ages 6 17 years with type 1 diabetes mellitus: A 12 month, outpatient, randomized, open label, parallel group comparative trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Insulin (Primary) ; Insulin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Oct 2018 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
    • 31 Aug 2018 Biomarkers information updated
    • 29 Apr 2010 Additional trial investigator [Rose A] identified as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top